Literature DB >> 15698877

Expanding indications for neuromodulation.

Andrew J Bernstein1, Kenneth M Peters.   

Abstract

Neuromodulation in one form or another has been studied for decades for various disease states. Although its mechanism of action remains un-explained, numerous clinical success stories suggest it is a therapy with efficacy and durability. Controlled studies have led to the approval of sacral neuromodulation for urinary urgency and frequency, urinary retention, and urinary urge incontinence. The future holds hopeful possibilities for the application of neuromodulation, namely in the areas of interstitial cystitis, in-tractable pain syndromes, fecal incontinence and constipation, spinal cord injury, and erectile dysfunction. Neuromodulators have also been used in nonurologic conditions, including chronic headaches and intractable chest pain. In adults and children, in the neurologically intact and neurologically impaired, neuromodulation has been shown to improve the quality of life of those suffering chronic disease states. Neuromodulation is changing the future of urology. Treatment of voiding dysfunction and likely other disorders, such as pelvic pain, sexual dysfunction, and bowel disorders, will no longer rely only on medications that are "OK" or destructive-reconstructive procedures that suffer from significant complications. Rather, by modulating the nerves, the urologists will treat these disorders in a minimally invasive fashion and neuromodulation will become the first-line therapy before any major surgery is undertaken.

Entities:  

Mesh:

Year:  2005        PMID: 15698877     DOI: 10.1016/j.ucl.2004.10.002

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  12 in total

Review 1.  Sacral neuromodulation and female sexuality.

Authors:  Giuseppe Lombardi; Enrico Finazzi Agrò; Giulio Del Popolo
Journal:  Int Urogynecol J       Date:  2015-04-16       Impact factor: 2.894

Review 2.  Sacral neuromodulation stimulation for IC/PBS, chronic pelvic pain, and sexual dysfunction.

Authors:  Jennifer Yonaitis Fariello; K Whitmore
Journal:  Int Urogynecol J       Date:  2010-12       Impact factor: 2.894

Review 3.  Sacral nerve stimulation in the elderly.

Authors:  Tomas L Griebling
Journal:  Int Urogynecol J       Date:  2010-12       Impact factor: 2.894

4.  Sacral nerve stimulation for treatment of intractable pain associated with cauda equina syndrome.

Authors:  Jong-Hoon Kim; Joo-Chul Hong; Min-Su Kim; Seong-Ho Kim
Journal:  J Korean Neurosurg Soc       Date:  2010-06-30

5.  Improvement of bowel dysfunction with sacral neuromodulation for refractory urge urinary incontinence.

Authors:  Bradley C Gill; Mia A Swartz; Raymond R Rackley; Courtenay K Moore; Howard B Goldman; Sandip P Vasavada
Journal:  Int Urogynecol J       Date:  2011-09-09       Impact factor: 2.894

6.  Autonomic-somatic communications in the human pelvis: computer-assisted anatomic dissection in male and female fetuses.

Authors:  Bayan Alsaid; David Moszkowicz; Frédérique Peschaud; Thomas Bessede; Mazen Zaitouna; Ibrahim Karam; Stéphane Droupy; Gérard Benoit
Journal:  J Anat       Date:  2011-07-22       Impact factor: 2.610

7.  Effects of sacral neuromodulation on female sexual function.

Authors:  Rachel N Pauls; Serge P Marinkovic; W Andre Silva; Christopher M Rooney; Steven D Kleeman; Mickey M Karram
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-07-26

8.  Sacral neuromodulation: Therapy evolution.

Authors:  Jannah H Thompson; Suzette E Sutherland; Steven W Siegel
Journal:  Indian J Urol       Date:  2010-07

9.  Sacral neuromodulation reprogramming: is it an office burden?

Authors:  Frank N Burks; Ananais C Diokno; Michelle J Lajiness; Ibrahim A Ibrahim; Kenneth M Peters
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-04-05

10.  Effect of sacral neuromodulation on female sexual function and quality of life: Are they correlated?

Authors:  Mai Banakhar; Yahya Gazwani; Mohamed El Kelini; Tariq Al-Shaiji; Magdy Hassouna
Journal:  Can Urol Assoc J       Date:  2014-11       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.